A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Krascendo 2
A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Patients With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
1 other identifier
interventional
600
28 countries
217
Brief Summary
The purpose of this study is to evaluate the efficacy and safety of divarasib and pembrolizumab compared with pembrolizumab and pemetrexed and carboplatin or cisplatin, for the first-line treatment of adult participants with KRAS G12C-mutated, advanced or metastatic non squamous non-small cell lung cancer (NSCLC).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_3 nonsmall-cell-lung-cancer
Started Oct 2025
Typical duration for phase_3 nonsmall-cell-lung-cancer
217 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 20, 2025
CompletedFirst Posted
Study publicly available on registry
January 27, 2025
CompletedStudy Start
First participant enrolled
October 24, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 30, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
October 31, 2030
April 13, 2026
April 1, 2026
3.1 years
January 20, 2025
April 9, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Progression-Free Survival (PFS)
PFS is defined as the time from randomization to the first occurrence of disease progression, as determined by blinded independent central review (BICR) according to RECIST v1.1, or death from any cause (whichever occurs first)
Up to approximately 5 years
Overall Survival (OS)
OS is defined as the time from randomization to death from any cause
Up to approximately 5 years
Secondary Outcomes (9)
Objective Response
Up to approximately 5 years
Change from Baseline on the European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire-Supplemental Lung Cancer Module (EORTC QLQ-LC13) Cough Scale
Baseline up to Cycle 5 Day 1 (each cycle is 21 days)
Change from Baseline on the EORTC Quality of Life Questionnaire (QLQ-C30) Dyspnea Item and Physical Functioning Scale
Baseline up to Cycle 5 Day 1 (each cycle is 21 days)
Duration of Response (DOR)
Up to approximately 5 years
Percentage of Participants with Adverse Events (AEs)
Up to approximately 5 years
- +4 more secondary outcomes
Study Arms (2)
Divarasib + Pembrolizumab
EXPERIMENTALParticipants will receive divarasib orally, once daily (QD) and pembrolizumab via intravenous (IV) infusion every 3 weeks (Q3W)
Pembrolizumab + Pemetrexed + Carboplatin or Cisplatin
ACTIVE COMPARATORParticipants will receive pembrolizumab, pemetrexed and carboplatin or cisplatin via IV infusion Q3W
Interventions
Pembrolizumab will be administered via IV infusion Q3W
Pemetrexed will be administered via IV infusion Q3W
Carboplatin will be administered via IV infusion Q3W
Cisplatin will be administered via IV infusion Q3W
Eligibility Criteria
You may qualify if:
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Histologically or cytologically confirmed diagnosis of advanced or metastatic non squamous NSCLC that is not eligible for curative surgery and/or definitive chemoradiotherapy
- Measurable disease, as defined by RECIST v1.1
- No prior systemic treatment for advanced or metastatic NSCLC
- Documentation of the presence of a KRAS G12C mutation
- Documentation of known PD-L1 expression status in tumor tissue
- Availability of a representative tumor specimen
- Adequate end-organ function
- Eligible to receive a platinum-based chemotherapy regimen
You may not qualify if:
- Known concomitant second oncogenic driver with available targeted treatment
- Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases
- Spinal cord compression not definitively treated with surgery and/or radiation or previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for \>=2 weeks prior to randomization
- History of leptomeningeal disease
- Uncontrolled tumor-related pain
- Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once a month or more frequently)
- Any anti-cancer systemic therapy, including hormonal therapy, within 21 days prior to randomization, or is expected to require any other form of antineoplastic therapy while in the study
- Radiation therapy including palliative RT to bone metastases within 2 weeks prior to randomization and RT to the lung \>30Gy within 6 months prior to randomization
- Prior treatment with KRAS G12C inhibitors or pan-KRAS/RAS inhibitors
- Treatment with systemic immunosuppressive or immunostimulatory medications, including CD137 agonists and immune checkpoint inhibitors
- Current treatment with medications that are well known to prolong the QT interval
- Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to randomization
- Prior allogeneic stem cell or solid organ transplantation
- History of malignancy other than NSCLC within 5 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death (e.g., 5-year overall survival \[OS\] rate \>90%), such as adequately treated carcinoma in situ of the cervix, non melanoma skin carcinoma, localized prostate cancer, ductal breast carcinoma in situ, or Stage I uterine cancer
- Individuals with chronic diarrhea, short bowel syndrome or significant upper gastrointestinal surgery including gastric resection, a history of inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis) or any active bowel inflammation (including diverticulitis), malabsorption syndrome, conditions that would interfere with enteral absorption
- +2 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Hoffmann-La Rochelead
- Chugai Pharmaceuticalcollaborator
Study Sites (217)
Alaska Oncology and Hematology
Anchorage, Alaska, 99508, United States
City of Hope - Phoenix
Goodyear, Arizona, 85338, United States
Marin Cancer Care Inc
Greenbrae, California, 94904, United States
Hoag Memorial Hospital
Newport Beach, California, 92658, United States
Florida Cancer Specialists - SOUTH - SCRI - PPDS
Fort Myers, Florida, 33901-8108, United States
BioResearch Partner
Hialeah, Florida, 33013, United States
Ascension Sacred Heart
Pensacola, Florida, 32504, United States
Florida Cancer Specialists - NORTH - SCRI - PPDS
St. Petersburg, Florida, 33701, United States
Florida Cancer Specialists - EAST - SCRI - PPDS
West Palm Beach, Florida, 33401-3406, United States
Piedmont Cancer Institute, PC
Atlanta, Georgia, 30318, United States
City of Hope® Atlanta
Newnan, Georgia, 30265, United States
Summit Cancer Care PC
Savannah, Georgia, 31405, United States
St. Luke's Cancer Institute
Boise, Idaho, 83712, United States
Affiliated Oncologists, LLC
Chicago Ridge, Illinois, 60415, United States
Hope and Healing Cancer Services
Hinsdale, Illinois, 60521, United States
City of Hope® Cancer Center Chicago
Zion, Illinois, 60099, United States
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
Profound Research, LLC
Farmington Hills, Michigan, 48334, United States
Missouri Baptist Medical Center
St Louis, Missouri, 63131, United States
San Juan Oncology Associates
Farmington, New Mexico, 87401, United States
Montefiore Einstein Cancer Center
The Bronx, New York, 10461, United States
Clinical Research Alliance
Westbury, New York, 11590, United States
Firsthealth of The Carolinas
Pinehurst, North Carolina, 28374, United States
Oregon Health and Science University
Portland, Oregon, 97239, United States
St. Luke's University Health Network
Bethlehem, Pennsylvania, 18015, United States
Reading Hospital - McGlinn Cancer Institute
West Reading, Pennsylvania, 19611, United States
Baptist Cancer Center
Memphis, Tennessee, 38120, United States
Renovatio Clinical - El Paso
El Paso, Texas, 79915, United States
JPS Health Network
Fort Worth, Texas, 76104, United States
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030-4000, United States
Community Clinical Trials
Kingwood, Texas, 77339, United States
Texas Tech Health Science Center
Lubbock, Texas, 79415, United States
Renovatio Clinical
The Woodlands, Texas, 77380, United States
University of Texas Health Center at Tyler
Tyler, Texas, 75708, United States
Virginia Oncology Associates
Norfolk, Virginia, 23502, United States
Hospital Britanico
Ciudad Autonoma Buenos Aires, C1280AEB, Argentina
Centro Oncologico Korben
Ciudad Autonoma Buenos Aires, C1426AGE, Argentina
Clinica Adventista Belgrano
Ciudad Autonoma Buenos Aires, C1430EGF, Argentina
Kinghorn Cancer Centre
Darlinghurst, New South Wales, 2010, Australia
Liverpool Hospital
Liverpool, New South Wales, 2170, Australia
Calvary Mater Newcastle
Waratah, New South Wales, 2298, Australia
Sunshine Coast University Hospital
Birtinya, Queensland, 4575, Australia
Royal Hobart Hospital
Hobart, Tasmania, 7000, Australia
Monash Health
Clayton, Victoria, 3168, Australia
Austin Health
Heidelberg, Victoria, 3084, Australia
Peter Maccallum Cancer Centre
Melbourne, Victoria, 3000, Australia
AZORG Campus Aalst-Moorselbaan
Aalst, 9300, Belgium
UZ Brussel
Brussels, 1090, Belgium
Cliniques Universitaires St-Luc
Brussels, 1200, Belgium
Jessa Zkh (Campus Virga Jesse)
Hasselt, 3500, Belgium
UZ Leuven Gasthuisberg
Leuven, 3000, Belgium
CHU de Liège (Sart Tilman)
Liège, 4000, Belgium
CHU HELORA - Hôpital de Mons - Site Kennedy
Mons, 7000, Belgium
AZ Delta (Campus Rumbeke)
Roeselare, 8800, Belgium
Crio - Centro Regional Integrado de Oncologia
Fortaleza, Ceará, 60336-232, Brazil
Centro Integrado de Oncologia de Curitiba
Curitiba, Paraná, 80810-050, Brazil
Liga Norte Riograndense Contra O Câncer
Natal, Rio Grande do Norte, 59040150, Brazil
Irmandade Da Santa Casa de Misericordia de Porto Alegre
Porto Alegre, Rio Grande do Sul, 90035-074, Brazil
Hospital Nossa Senhora da Conceicao
Porto Alegre, Rio Grande do Sul, 90040-373, Brazil
Fundação Pio XII Hospital de Câncer de Barretos
Barretos, São Paulo, 14784-400, Brazil
Instituto do Cancer do Estado de Sao Paulo - ICESP
São Paulo, São Paulo, 01246-000, Brazil
BC Cancer ? Kelowna (Sindi Ahluwalia Hawkins Centre)
Kelowna, British Columbia, V1Y 5L3, Canada
BC Cancer - Victoria
Victoria, British Columbia, V8R 6V5, Canada
Royal Victoria Regional Health Centre
Barrie, Ontario, L4M 6M2, Canada
William Osler Health Centre - Brampton Civic Hospital
Brampton, Ontario, L6R 3J7, Canada
Jewish General Hospital
Montreal, Quebec, H3T 1E2, Canada
Centre Hospitalier Regional De Rimouski
Rimouski, Quebec, G5L 5T1, Canada
Saskatoon Cancer Centre
Saskatoon, Saskatchewan, S7N 4H4, Canada
Hunan Cancer Hospital
Changsha, 410013, China
West China Hospital - Sichuan University
Chengdu, 611130, China
Sir Run Run Shaw Hospital Zhejiang University
Hangzhou, 310016, China
Harbin Medical University Cancer Hospital
Harbin, 150081, China
Shanghai East Hospital
Shanghai, 200120, China
Shanghai Pulmonary Hospital
Shanghai, 200433, China
Aarhus Universitetshospital
Aarhus N, 8200, Denmark
Herlev Hospital, Afdeling for Kræftbehandling, Center for Kræftforskning, Klinisk Forskningsenhed
Herlev, 2730, Denmark
Rigshospitalet
København Ø, 2100, Denmark
Sjællands Universitetshospital, Roskilde
Roskilde, 4000, Denmark
Onkologisk Ambulatorium - Sønderborg
Sønderborg, 6400, Denmark
CHU Angers
Angers, 49933, France
Hopital Avicenne
Bobigny, 93009, France
Hôpital Louis Pradel, Hospices Civils de Lyon
Bron, 69677, France
Centre Francois Baclesse
Caen, 14076, France
Centre Leon Berard
Lyon, 69008, France
CHU Montpellier
Montpellier, 34295, France
Centre Antoine Lacassagne
Nice, 06189, France
Groupe Hospitalier Paris Saint Joseph
Paris, 75014, France
Hopital Tenon
Paris, 75970, France
CHU Bordeaux
Pessac, 33604, France
Centre Hospitalier Universitaire de Reims
Reims, 51092, France
CH de Saint Quentin
Saint-Quentin, 02321, France
CHU Strasbourg - Nouvel Hopital Civil
Strasbourg, 67091, France
Centre Hospitalier Bretagne Atlantique Vannes
Vannes, 56017, France
Vivantes - Klinikum Im Friedrichshain;Innere Medizin ? Hämatologie, Onkologie und Palliativmedizin
Berlin, 10249, Germany
Charite - Universitätsmedizin Berlin
Berlin, 13353, Germany
Technische Universität Dresden - Medizinische Fakultät Carl Gustav Carus;Medizinische Klinik und Poliklinik I
Dresden, 01307, Germany
KEM/Evang. Kliniken Essen Mitte gGmbH
Essen, 45136, Germany
Universitätsklinikum Essen
Essen, 45147, Germany
Klinikum Esslingen
Esslingen am Neckar, 73730, Germany
Asklepios Fachkliniken GmbH
Gauting, 82131, Germany
Krankenhaus Martha-Maria Halle-Doelau gGmbH
Halle, 06120, Germany
Universitätsklinikum Hamburg-Eppendorf
Hamburg, 20246, Germany
KRH Klinikum Siloah-Oststadt-Heidehaus
Hanover, 30459, Germany
Universität Des Saarlandes
Homburg, 66421, Germany
Lungenfachklinik Immenhausen
Immenhausen, 34376, Germany
Vincentius-Diakonissen-Kliniken gAG
Karlsruhe, 76137, Germany
SLK Kliniken Heilbronn GmbH, Standort Fachklinik Löwenstein
Löwenstein, 74245, Germany
Universität Mannheim
Mannheim, 68167, Germany
Pius Hospital Oldenburg
Oldenburg, 26121, Germany
Universitätsklinikum Regensburg
Regensburg, 93053, Germany
Klinikum Würzburg Mitte gGmbH
Würzburg, 97074, Germany
Sotiria General Hospital of Athens
Athens, 115 27, Greece
Alexandras Hospital
Athens, 115 28, Greece
Errikos Dynan Hospital
Athens, 11526, Greece
University Hospital of Larissa
Larissa, 411 10, Greece
Interbalkan Medical Center of Thessaloniki
Thessaloniki, 546 39, Greece
Theageneion Anticancer Hospital
Thessaloniki, 54639, Greece
Ag. Loukas Hospital
Thessaloniki, 55236, Greece
Queen Mary Hospital
Hong Kong, Hong Kong
Tuen Mun Hospital
Hong Kong, Hong Kong
Queen Elizabeth Hospital Department of Clinical Oncology
Kowloon, 000000, Hong Kong
Prince of Wales Hosp
Shatin, Hong Kong
Matrai Gyogyintezet
Mátraháza, 3233, Hungary
Református Pulmonológiai Centrum
Törökbálint, 2045, Hungary
St James Hospital
Dublin, D08 NHY1, Ireland
Beaumont Hospital
Dublin, D09V2N0, Ireland
Tallaght Hospital
Dublin, D24 NR0A, Ireland
Mater Misecordiae University Hospital
Dublin, Dublin 7, Ireland
Ospedale Giuseppe Moscati
Statte, Apulia, 74010, Italy
AORN Ospedali dei Colli Ospedale Monaldi
Naples, Campania, 80131, Italy
Istituto Nazionale Tumori Fondazione G. Pascale
Naples, Campania, 80131, Italy
A.O. Universitaria Policlinico Di Modena
Modena, Emilia-Romagna, 41100, Italy
Presidio san salvatore muraglia
Pesaro, Emilia-Romagna, 61122, Italy
Irccs Centro Di Riferimento Oncologico (CRO)
Aviano, Friuli Venezia Giulia, 33081, Italy
Azienda Ospedaliera San Camillo Forlanini
Rome, Lazio, 00151, Italy
Policlinico Universitario "Agostino Gemelli"
Rome, Lazio, 00168, Italy
IEO Istituto Europeo di Oncologia
Milan, Lombardy, 20141, Italy
Azienda Socio Sanitaria Territoriale Niguarda (Ospedale Niguarda Ca' Granda)
Milan, Lombardy, 20162, Italy
Humanitas Centro Catanese Di Oncologia
Misterbianco (CT), Sicily, 95045, Italy
USL 6 Toscana Nord Ovest ? P.O. Livorno
Livorno, Tuscany, 57124, Italy
Ospedale P. Pederzoli Casa di cura Privata
Peschiera Del Garda (VR), Veneto, 37019, Italy
Kyushu University Hospital
Fukuoka, 812-8582, Japan
Kurume University Hospital
Fukuoka, 830-0011, Japan
Hyogo Medical University Hospital
Hyōgo, 663-8501, Japan
Kagoshima University Hospital
Kagoshima, 890-8520, Japan
Kanagawa Cancer Center
Kanagawa, 241-8515, Japan
Sendai Kousei Hospital
Miyagi, 981-0914, Japan
Niigata University Medical & Dental Hospital
Niigata, 951-8520, Japan
Okayama University Hospital
Okayama, 700-8558, Japan
Osaka Metropolitan University Hospital
Osaka, 545-8586, Japan
Kansai Medical University Hospital
Osaka, 573-1191, Japan
Tohoku University Hospital
Sendai, 980-8574, Japan
The Cancer Institute Hospital of JFCR
Tokyo, 135-8550, Japan
ARKE Estudios Clínicos S.A. de C.V.
Mexico City, 06700, Mexico
Meander Medisch Centrum
Amersfoort, Utrecht, 3813 TZ, Netherlands
Ziekenhuis Rijnstate
Arnhem, 6815 AD, Netherlands
Amphia Ziekenhuis
Breda, 4818 CK, Netherlands
Ziekenhuis St. Jansdal
Harderwijk, 3844 DG, Netherlands
Isala
Zwolle, 8025 AB, Netherlands
Harbour Cancer and Wellness
Auckland, 1023, New Zealand
Centrum Pulmonologii i Torakochirurgii
Bystra, 43-360, Poland
Uniwersyteckie Centrum Kliniczne
Gda?sk, 80-214, Poland
Krakowski Szpital Specjalistyczny im sw.Jana Pawla II
Krakow, 31-202, Poland
Uniwersytecki Szpital Kliniczny nr 4 w Lublinie
Lublin, 20-954, Poland
Warminsko-Mazurskie Centrum Chorób P?uc w Olsztynie
Olsztyn, 10-357, Poland
Wielkopolskie Centrum Pulmonologii i Torakochirurgii w Poznaniu
Poznan, 60-569, Poland
Radomskie Centrum Onkologii
Radom, 26-600, Poland
Instytut Gruzlicy I Chorob Pluc
Warsaw, 01-138, Poland
Mazowiecki Szpital Onkologiczny
Wieliszew, 05-135, Poland
Dolnoslaskie Centrum Chorob Pluc
Wroclaw, 53-439, Poland
Hospital de Braga
Braga, 4710-243, Portugal
Hospital Beatriz Angelo
Loures, 2674-514, Portugal
IPO do Porto
Porto, 4200-072, Portugal
CHVNG/E_Unidade 1
Vila Nova de Gaia, 4434-502, Portugal
National University Hospital
Singapore, 119228, Singapore
National Cancer Centre
Singapore, 168583, Singapore
Wits Donald Gordon Clinical Trial Centre
Parktown, South Africa
Chris Hani Baragwanath Clinical Trial Site
Soweto, 2013, South Africa
Pusan National University Hospital
Busan, 49241, South Korea
Chungbuk National University Hospital
Cheongju-si, 28644, South Korea
Kyungpook National University Chilgok Hospital
Daegu, 41404, South Korea
The Catholic University of Korea, Seoul St. Mary's Hospital
Seoul, 06591, South Korea
Seoul National University Hospital
Seoul, 110-744, South Korea
Korea University Guro Hospital
Seoul, 8308, South Korea
Hospital Universitario Son Espases
Palma de Mallorca, Balearic Islands, 07014, Spain
Hospital Universitario Marques de Valdecilla
Santander, Cantabria, 39008, Spain
Clinica Universitaria de Navarra
Pamplona, Navarre, 31008, Spain
Vall d'Hebron Institute of Oncology (VHIO), Barcelona
Barcelona, 08035, Spain
Hospital Clinic Barcelona
Barcelona, 08036, Spain
Hospital de la Santa Creu i Sant Pau
Barcelona, 08041, Spain
Clinica Universidad de Navarra Madrid
Madrid, 28027, Spain
Hospital Ramon y Cajal
Madrid, 28034, Spain
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
Hospital Universitario La Paz
Madrid, 28046, Spain
Hospital Clinico Universitario Virgen de la Victoria
Málaga, 29010, Spain
Hospital Universitario Virgen Macarena
Seville, 41009, Spain
Hospital Clínico Universitario de Valencia
Valencia, 46010, Spain
Kantonsspital Baden
Baden, 5404, Switzerland
Universitaetsspital Basel
Basel, 4031, Switzerland
Kantonsspital Graubünden Medizin Onkologie
Chur, 7000, Switzerland
Hôpital Universitaire de Genève (HUG)
Geneva, 1211, Switzerland
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, 80756, Taiwan
E-DA Hospital
Kaohsiung City, 824, Taiwan
Chung Shan Medical University Hospital
Taichung, 40201, Taiwan
National Taiwan University Hospital
Taipei, 00100, Taiwan
Taipei Medical University Hospital
Taipei, 110, Taiwan
Taipei Veterans General Hospital
Taipei, 112, Taiwan
National Taiwan University Cancer Center
Zhongzheng Dist., 106, Taiwan
Blackpool Teaching Hospitals NHS Foundation Trust , Victoria Hospital
Blackpool, FY3 8NR, United Kingdom
Bristol Haematology & Oncology Centre
Bristol, BS2 8ED, United Kingdom
East Kent Hospitals University NHS Foundation Trust
Canterbury, CT1 3NG, United Kingdom
Velindre NHS Trust - Velindre Cancer Centre
Cardiff, CF14 2TL, United Kingdom
Barts and the London NHS Trust
London, E1 2ES, United Kingdom
Royal Marsden Hospital - Fulham
London, SW3 6JJ, United Kingdom
Sarah Cannon Research Institute
London, W1G 6AD, United Kingdom
Maidstone and Tunbridge Wells NHS Trust
Maidstone, ME16 9QQ, United Kingdom
Royal Marsden NHS Foundation Trust
Sutton, SM2 5PT, United Kingdom
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Clinical Trials
Hoffmann-La Roche
Central Study Contacts
Reference Study ID Number: CO45042 https://forpatients.roche.com/
CONTACT
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 20, 2025
First Posted
January 27, 2025
Study Start
October 24, 2025
Primary Completion (Estimated)
November 30, 2028
Study Completion (Estimated)
October 31, 2030
Last Updated
April 13, 2026
Record last verified: 2026-04
Data Sharing
- IPD Sharing
- Will share
For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data\_sharing